<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Eli on Tenu Tech Brief</title>
    <link>https://cluster-site.onrender.com/tags/eli/</link>
    <description>Recent content in Eli on Tenu Tech Brief</description>
    <generator>Hugo -- 0.146.0</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 24 Feb 2026 06:03:57 +0000</lastBuildDate>
    <atom:link href="https://cluster-site.onrender.com/tags/eli/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug</title>
      <link>https://cluster-site.onrender.com/posts/eli-lilly-joins-chase-for-hot-inflammation-target-paying-100m-for-rights-to-csl-drug/</link>
      <pubDate>Wed, 18 Feb 2026 17:56:25 +0000</pubDate>
      <guid>https://cluster-site.onrender.com/posts/eli-lilly-joins-chase-for-hot-inflammation-target-paying-100m-for-rights-to-csl-drug/</guid>
      <description>• CSL Limited retains rights to clazakizumab in end-stage kidney disease. • Eli Lilly gets rights to the the IL-6-blocking antibody in other indications that could put it in compet</description>
    </item>
  </channel>
</rss>
